<table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Trial name (Trial ID)</th><th valign="middle" align="left" rowspan="1" colspan="1">Design</th><th valign="top" align="left" rowspan="1" colspan="1">Population</th><th valign="top" align="left" rowspan="1" colspan="1">Drug ang dose</th><th valign="top" align="left" rowspan="1" colspan="1">Primary endpoint</th><th valign="top" align="left" rowspan="1" colspan="1">Result</th><th valign="top" align="left" rowspan="1" colspan="1">Conclusion</th><th valign="top" align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">COVAC-TP (NCT04354155)</td><td valign="top" align="left" rowspan="1" colspan="1">Phase 2 open-label single-arm</td><td valign="top" align="left" rowspan="1" colspan="1">Children hospitalized for symptomatic COVID-19 (n=40)</td><td valign="top" align="left" rowspan="1" colspan="1">Enoxaparin<break/>Initial dose: 0.5mg/kg bid;<break/>max: 60mg.</td><td valign="top" align="left" rowspan="1" colspan="1">Efficacy: Cumulative incidence of VTE within 30 days post-discharge.<break/>Safety: ISTH-defined clinically-relevant bleeding (30 days).</td><td valign="top" align="left" rowspan="1" colspan="1">No clinically relevant bleeding. Two children (5.3%) developed central-venous catheter-related venous thromboembolism. No serious adverse events.</td><td valign="top" align="left" rowspan="1" colspan="1">Among children hospitalized for COVID-19, thromboprophylaxis with twice-daily enoxaparin appears safe.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B105" ref-type="bibr">105</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ASPEN-COVID-19 (NCT04655586)</td><td valign="top" align="left" rowspan="1" colspan="1">Multicenter RCT</td><td valign="top" align="left" rowspan="1" colspan="1">People hospitalized with COVID&#8208;19<break/> (n=160)</td><td valign="top" align="left" rowspan="1" colspan="1">Intervention: rNAPc2 (high/low dose)<break/>Control: Standard heparin</td><td valign="top" align="left" rowspan="1" colspan="1">Efficacy: Proportional change in D-dimer (baseline to Day 8/discharge).<break/>Safety: Major or non-major clinically relevant bleeding (Day 8).</td><td valign="top" align="left" rowspan="1" colspan="1">There was no significant difference in terms of safety between rNAPc2 and heparin.Median change in D-dimer was -16.8% (interquartile range, -45.7 to 36.8; P=0.41) with rNAPc2 treatment and -11.2% (-36.0 to 34.4; P=0.91) with heparin (Pintergroup=0.47).</td><td valign="top" align="left" rowspan="1" colspan="1">rNAPc2 treatment in hospitalized patients with COVID-19 was well tolerated without excess bleeding or serious adverse events but did not significantly reduce D-dimer more than heparin at day 8.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B106" ref-type="bibr">106</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HERO-19 (NCT04542408)</td><td valign="top" align="left" rowspan="1" colspan="1">A prospective, multicenter, interventional Phase III trial</td><td valign="top" align="left" rowspan="1" colspan="1">People with COVID&#8208;19<break/> (n=140)</td><td valign="top" align="left" rowspan="1" colspan="1">Intervention:<break/>- Inpatient: Weight-adjusted therapeutic LMWH<break/>- Post-discharge: Edoxaban 60mg qd<break/>Control:<break/>- Inpatient: Prophylactic LMWH<break/>- Post-discharge: Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">Efficacy: 42-day all-cause death, VTE, or ATE.</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FREEDOM COVID (NCT04512079)</td><td valign="top" align="left" rowspan="1" colspan="1">3-arm open-label RCT</td><td valign="top" align="left" rowspan="1" colspan="1">Noncritically ill patients hospitalized with COVID-19 (n=3398)</td><td valign="top" align="left" rowspan="1" colspan="1">A: Apixaban 5mg bid<break/>B: Enoxaparin 1mg/kg bid<break/>C: Enoxaparin 40mg qd</td><td valign="top" align="left" rowspan="1" colspan="1">Efficacy: 30-day composite: all-cause death, ICU need, thromboembolism, or ischemic stroke.<break/>Safety: Major bleeding (BARC types 3 or 5).</td><td valign="top" align="left" rowspan="1" colspan="1">The 30-day primary outcome rate was 13.2% (in the preventive dose group) vs. 11.3% (in the therapeutic dose group) (HR: 0.85; 95% CI: 0.69 - 1.04; P = 0.11). The all-cause mortality rate was 7.0% vs. 4.9% (HR: 0.70; 95% CI: 0.52 - 0.93; P = 0.01), intubation rate was 8.4% vs. 6.4% (HR: 0.75; 95% CI: 0.58 - 0.98; P = 0.03). Intravascular hemorrhage (the primary safety endpoint) was not common, 0.1% VS 0.4%</td><td valign="top" align="left" rowspan="1" colspan="1">Therapeutic anticoagulation did not reduce the 30-day composite outcome in noncritically ill COVID-19 inpatients vs. prophylactic dosing; however, it reduced intubation and mortality.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B107" ref-type="bibr">107</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACTION (NCT04394377)</td><td valign="top" align="left" rowspan="1" colspan="1">Open-label RCT</td><td valign="top" align="left" rowspan="1" colspan="1">Patients hospitalized with COVID-19 and elevated D-dimer concentration (n=3331)</td><td valign="top" align="left" rowspan="1" colspan="1">Intervention: Rivaroxaban (20 mg or 15 mg qd) or enoxaparin (1 mg/kg bid)&#8594;rivaroxaban<break/>Control: Prophylactic heparin</td><td valign="top" align="left" rowspan="1" colspan="1">Efficacy: Hierarchical composite: time to death, hospitalization duration, or oxygen use (30 days).<break/>Safety: Major or clinically relevant non-major bleeding.</td><td valign="top" align="left" rowspan="1" colspan="1">Primary efficacy outcome: 34.8% (therapeutic) vs 41.3% (preventive) (win ratio 0.86 [95% CI 0.59 - 1.22], p = 0.40).<break/>Primary safety outcome: 5.8% (therapeutic) vs 2% (preventive) (relative risk 3.64 [95% CI 1.61 - 8.27], p = 0.0010).</td><td valign="top" align="left" rowspan="1" colspan="1">In hospitalized COVID-19 patients with elevated D-dimer, therapeutic rivaroxaban or enoxaparin failed to improve 30-day outcomes and increased bleeding vs. prophylactic heparin. Avoid therapeutic oral anticoagulants without evidence-based indications.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B108" ref-type="bibr">108</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATTACC (NCT04372589)</td><td valign="top" align="left" rowspan="1" colspan="1">A prospective, open-label, multicenter RCT</td><td valign="top" align="left" rowspan="1" colspan="1">Noncritically Ill Patients with Covid-19 (n=1200)</td><td valign="top" align="left" rowspan="1" colspan="1">enoxaparin 1.5 mg/kg qd or 1 mg/kg bid sc (14 days)</td><td valign="top" align="left" rowspan="1" colspan="1">Efficacy: Mortality and days free of organ support</td><td valign="top" align="left" rowspan="1" colspan="1">Unknow</td><td valign="top" align="left" rowspan="1" colspan="1">Unknow</td><td valign="top" align="left" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RAPID (NCT04362085)</td><td valign="top" align="left" rowspan="1" colspan="1">A randomized controlled, adaptive, open label clinical trial</td><td valign="top" align="left" rowspan="1" colspan="1">moderately ill patients with covid-19 admitted to hospital wards (n=465)</td><td valign="top" align="left" rowspan="1" colspan="1">LMWH or UFH<break/>Intervention: Therapeutic dose of LMWH or high dose nomogram of UFH.<break/>Control: thromboprophylactic doses of LMWH or UFH.</td><td valign="top" align="left" rowspan="1" colspan="1">Efficacy: 28-day composite of death, mechanical ventilation (invasive/non-invasive), or ICU admission.<break/>Safety: Major bleeding.</td><td valign="top" align="left" rowspan="1" colspan="1">Main composite outcome: 16.2% (therapeutic heparin) vs. 21.9% (preventive heparin) (OR 0.69, 95% CI 0.43 - 1.10; P = 0.12).<break/>Major bleeding: 0.9% (therapeutic heparin) vs. 1.7% (preventive heparin) (OR 0.52, 95% CI 0.09 - 2.85; P = 0.69).</td><td valign="top" align="left" rowspan="1" colspan="1">Therapeutic heparin did not reduce the 28-day composite outcome (death/mechanical ventilation/ICU admission) in moderately ill ward patients with elevated D-dimer but reduced 28-day mortality with low major bleeding risk.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B109" ref-type="bibr">109</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATTACC, ACTIV-4a, and REMAP-CAP (NCT04372589, NCT04505774, NCT04359277, NCT02735707)</td><td valign="top" align="left" rowspan="1" colspan="1">An open-label, adaptive, multiplatform, randomized clinical trial</td><td valign="top" align="left" rowspan="1" colspan="1">noncritically ill patients with Covid-19 (n=2219)</td><td valign="top" align="left" rowspan="1" colspan="1">LMWH or UFH<break/>Intervention: Therapeutic-dose anticoagulation.<break/>Control: Thromboprophylaxis was provided at a dose and duration determined by the treating clinician according to local practice.</td><td valign="top" align="left" rowspan="1" colspan="1">Efficacy: Organ support-free days<break/>Safety: Major bleeding.</td><td valign="top" align="left" rowspan="1" colspan="1">the probability that therapeutic-dose anticoagulation increased organ support&#8211;free days was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58).<break/>Major bleeding: 1.9% (treatment dose anticoagulation) vs 0.9% (usual-care thromboprophylaxis).</td><td valign="top" align="left" rowspan="1" colspan="1">In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B110" ref-type="bibr">110</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ATTACC, ACTIV-4a, and REMAP-CAP (NCT04372589, NCT04505774, NCT04359277, NCT02735707)</td><td valign="top" align="left" rowspan="1" colspan="1">An open-label, adaptive, multiplatform, randomized clinical trial</td><td valign="top" align="left" rowspan="1" colspan="1">critically ill patients with severe Covid-19 (n=1098)</td><td valign="top" align="left" rowspan="1" colspan="1">LMWH or UFH<break/>Intervention: Therapeutic-dose anticoagulation was up to 14 days or until recovery.<break/>Control: Usual-care thromboprophylaxis was administered at a dose and duration determined by the treating clinician according to local practice.</td><td valign="top" align="left" rowspan="1" colspan="1">Efficacy: Organ support-free days<break/>Safety: Major bleeding.</td><td valign="top" align="left" rowspan="1" colspan="1">(treatment dose anticoagulation) VS (usual-care thromboprophylaxis).<break/>The median value for organ support&#8211;free days:1 vs 4 (interquartile range, -1 to 16)<break/> (adjusted proportional odds ratio, 0.83; 95%CI, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio &lt;1.2], 99.9%).<break/>The percentage of patients who survived to hospital discharge was similar in the two groups (62.7% vs 64.5%, respectively; adjusted odds ratio, 0.84; 95% CI 0.64-1.11).</td><td valign="top" align="left" rowspan="1" colspan="1">In critically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin did not result in a greater probability of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support than did usual-care pharmacologic thromboprophylaxis.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B111" ref-type="bibr">111</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">COVID-PACT (NCT04409834)</td><td valign="top" align="left" rowspan="1" colspan="1">A multicenter, open-label, randomized-controlled trial</td><td valign="top" align="left" rowspan="1" colspan="1">critically-ill hospitalized patients with COVID&#8208;19<break/> (n=390)</td><td valign="top" align="left" rowspan="1" colspan="1">LMWH<break/>Intervention: Full-dose anticoagulation for prophylaxis<break/>Control: Standard-dose prophylactic anticoagulation</td><td valign="top" align="left" rowspan="1" colspan="1">Efficacy: Composite VTE/ATE.<break/>primary safety outcome: fatal or life-threatening bleeding.<break/>secondary safety outcome: moderate to severe bleeding</td><td valign="top" align="left" rowspan="1" colspan="1">12.3% (full-dose) vs 6.4% (standard-dose); win ratio, 1.95 [95% CI, 1.08 - 3.55]; P = 0.028).<break/>Primary efficacy endpoint: 9.9% (full-dose) vs 15.2% (standard-dose); HR, 0.56 [95% CI, 0.32 - 0.99]; P = 0.046).<break/>Primary safety endpoint: 2.1% vs 0.5% (P = 0.19);<break/>Secondary safety endpoint: 7.9% vs 0.5%; P = 0.002.<break/>There was no difference in all-cause mortality (risk ratio, 0.91 [95% CI, 0.56 - 1.48]; P = 0.70).<break/>There was no difference in the primary efficacy or safety endpoints between clopidogrel and no antiplatelet treatment.</td><td valign="top" align="left" rowspan="1" colspan="1">Full-dose anticoagulation (without clopidogrel) reduced thrombotic complications but increased bleeding (primarily transfusions) without excess mortality in critically ill COVID-19 patients.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B112" ref-type="bibr">112</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">The HEP-COVID Randomized Clinical Trial (NCT04401293)</td><td valign="top" align="left" rowspan="1" colspan="1">Open-label RCT</td><td valign="top" align="left" rowspan="1" colspan="1">Critically-ill hospitalised patients with COVID-19 with D-dimer levels more than 4 times the upper limit of normal or sepsis-induced coagulopathy score of 4 or greater (n=257)</td><td valign="top" align="left" rowspan="1" colspan="1">LMWH<break/>Intervention: Full dose LMWH anticoagulation therapy (enoxaparin).<break/>Control: Prophylactic/Intermediate dose LMWH or UFH therapy.</td><td valign="top" align="left" rowspan="1" colspan="1">Efficacy: VTE, ATE, or all-cause death.<break/>Safety: Major bleeding (30 &#8201;&#177;&#8201;2 days).</td><td valign="top" align="left" rowspan="1" colspan="1">Primary efficacy endpoint: 41.9% (standard-dose) vs 28.7% (therapeutic-dose) (RR, 0.68; 95% CI, 0.49-0.96; P = 0.03)<break/>Reduction in thromboembolism: (29.0% vs 10.9%; RR, 0.37; 95% CI, 0.21-0.66; P &lt; 0.001).<break/>The primary efficacy endpoint was reduced in non-ICU patients (36.1% vs 16.7%; RR, 0.46; 95% CI, 0.27-0.81; P = 0.004), but not in ICU patients (55.3% vs 51.1%; RR, 0.92; 95% CI, 0.62-1.39; P&#8201;=0&#8201;.71).<break/>Major bleeding: 1.6% (standard dose) vs 4.7% (treatment dose) (RR, 2.88; 95% CI, 0.59 - 14.02; P = 0.17).</td><td valign="top" align="left" rowspan="1" colspan="1">In this randomized clinical trial, therapeutic-dose LMWH reduced major thromboembolism and death compared with institutional standard heparin thromboprophylaxis among inpatients with COVID-19 with very elevated D-dimer levels. The treatment effect was not seen in ICU patients.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B113" ref-type="bibr">113</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HESACOVID (REBEC RBR-949z6v)</td><td valign="top" align="left" rowspan="1" colspan="1">A randomized, open-label, phase II study</td><td valign="top" align="left" rowspan="1" colspan="1">Critically-ill hospitalised patients with COVID-19 requiring mechanical ventilation (n=20)</td><td valign="top" align="left" rowspan="1" colspan="1">Enoxaparin<break/>The therapeutic enoxaparin group was allocated to receive subcutaneous enoxaparin.<break/>The standard thromboprophylaxis group was allocated to receive subcutaneous UFH at a dose of 5000 IU TID (if weight &lt; 120 kg) and 7500 IU TID (if weight &gt; 120 kg) or enoxaparin at a dose of 40 mg OD (if weight &lt; 120 kg) and 40 mg BID (if weight &gt; 120 Kg).</td><td valign="top" align="left" rowspan="1" colspan="1">Efficacy: PaO&#8322;/FiO&#8322; ratio change (baseline &#8594; Day 7/14).<break/>Safety: Major bleeding</td><td valign="top" align="left" rowspan="1" colspan="1">The PaO2/FiO2 ratio over time in the therapeutic t enoxaparin group (163 [95% confidence interval &#8211; CI 133&#8211;193] at baseline, 209 [95% CI 171&#8211;247] after 7 days, and 261 [95% CI 230&#8211;293] after 14 days), p = 0.0004.<break/>prophylactic group (184 [95% CI 146&#8211;222] at baseline, 168 [95% CI 142&#8211;195] after 7 days, and 195 [95% CI 128&#8211;262] after 14 days), p = 0.487.<break/>The therapeutic group had a higher ratio of successful liberation from mechanical ventilation (hazard ratio: 4.0 [95% CI 1.035&#8211;15.053]), p = 0.031 and more ventilator-free days (15 days [interquartile range IQR 6&#8211;16] versus 0 days [IQR 0&#8211;11]), p = 0.028 when compared to the prophylactic group.</td><td valign="top" align="left" rowspan="1" colspan="1">Therapeutic enoxaparin improves gas exchange and decreases the need for mechanical ventilation in severe COVID-19</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B114" ref-type="bibr">114</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NCT04360824</td><td valign="top" align="left" rowspan="1" colspan="1">A prospective, open-label, multi-center RCT</td><td valign="top" align="left" rowspan="1" colspan="1">People hospitalized with COVID&#8208;19 and admitted to an intensive care unit (ICU) and/or had laboratory evidence of coagulopathy (n=176)</td><td valign="top" align="left" rowspan="1" colspan="1">standard prophylactic dose enoxaparin (40 mg SC qd if BMI &lt;30 kg/m2; 30 mg SC bid or 40 mg SC bid if BMI &#8805; 30 kg/m2).<break/>intermediate-dose enoxaparin (1 mg/kg SC qd if BMI &lt;30 kg/m2 or 0.5 mg/kg SC bid if BMI &#8805; 30 kg/m2)</td><td valign="top" align="left" rowspan="1" colspan="1">Primary outcome: all&#8208;cause mortality at 30 days.<break/>Secondary outcome: arterial or venous thromboembolism and major bleeding</td><td valign="top" align="left" rowspan="1" colspan="1">All&#8208;cause mortality at 30 days:15% (intermediate dose enoxaparin)VS 21% (standard dose enoxaparin) (OR, 0.66;95%CI, 0.30-1.45;P =0.31 by Chi&#8208;square test)&#12290;<break/>Arterial or venous thrombosis:13% (intermediate dose enoxaparin)VS 9% (standard dose enoxaparin)&#12290;<break/>Major bleeding occurred in 2% of patients in each arm.</td><td valign="top" align="left" rowspan="1" colspan="1">In hospitalized adults with severe COVID&#8208;19, standard prophylactic dose and intermediate dose enoxaparin did not differ significantly in preventing death or thrombosis at 30 days.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B115" ref-type="bibr">115</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">INSPIRATION (NCT04486508)</td><td valign="top" align="left" rowspan="1" colspan="1">Open-label RCT</td><td valign="top" align="left" rowspan="1" colspan="1">Patients with COVID-19 admitted to intensive care (n=562)</td><td valign="top" align="left" rowspan="1" colspan="1">Intervention: Enoxaparin 1mg/kg qd<break/>Control: Enoxaparin 40mg qd</td><td valign="top" align="left" rowspan="1" colspan="1">Efficacy: Composite: venous/arterial thrombosis, ECMO, or all-cause death.<break/>Safety: Major bleeding.</td><td valign="top" align="left" rowspan="1" colspan="1">primary outcome:45.7% (intermediate-dose prophylactic anticoagulation)VS 44.1% (standard-dose prophylactic anticoagulation) (OR, 1.06).</td><td valign="top" align="left" rowspan="1" colspan="1">Intermediate-dose compared with standard-dose prophylactic anticoagulation did not reduce a composite of death, treatment with ECMO, or venous or arterial thrombosis at 90-day follow-up. It not support routine empirical use of intermediate-dose prophylactic anticoagulation in unselected patients with COVID-19 admitted to the ICU.</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B116" ref-type="bibr">116</xref>)</td></tr></tbody></table>